BRAF and melanoma: After the approval of BRAF inhibitor such as vemurafenib or dabrafenib by the United States Food and Drug Administration in 2011, there has been a significant improvement in the progression-free and overall survival in melanoma patients with metastasis and BRAF V600 mutation in comparison to chemotherapy [1, 2].